Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2001
10/10/2001EP1140986A1 Pseudopeptide, synthesis method, reagent and applications
10/10/2001EP1140985A1 Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
10/10/2001EP1140984A1 Selective inhibitors of mmp-12
10/10/2001EP1140983A1 Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors
10/10/2001EP1140981A1 Tripeptide compounds useful as selective inhibitors of aminopeptidase a and corresponding pharmaceutical compositions
10/10/2001EP1140980A1 Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same
10/10/2001EP1140979A1 Polyol compounds, their production and use
10/10/2001EP1140978A1 Methods of identifying antigen gene sequences
10/10/2001EP1140976A2 Secreted proteins and uses thereof
10/10/2001EP1140975A1 Stable subtilin and methods of manufacture
10/10/2001EP1140970A1 47 human secreted proteins
10/10/2001EP1140969A1 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140964A2 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140918A1 Thrombin inhibitors
10/10/2001EP1140909A1 Novel inhibitors of farnesyl-protein transferase
10/10/2001EP1140896A1 Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
10/10/2001EP1140851A1 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
10/10/2001EP1140837A1 Compounds useful in the treatment of inflammatory diseases
10/10/2001EP1140290A2 Synergistic tumorcidal response induced by histamine
10/10/2001EP1140240A1 Injectable hyaluronic acid derivative with pharmaceuticals/cells
10/10/2001EP1140214A1 Removal of biological contaminants
10/10/2001EP1140205A2 GENE THERAPY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING Na,K-ATPase
10/10/2001EP1140204A2 Vitronectin receptor antagonist pharmaceuticals
10/10/2001EP1140202A1 Peptidic product, process and composition
10/10/2001EP1140199A1 Hyaluronate lyase used for promoting penetration in topical agents
10/10/2001EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
10/10/2001EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
10/10/2001EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
10/10/2001EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
10/10/2001EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
10/10/2001EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
10/10/2001EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia
10/10/2001EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia
10/10/2001EP1140174A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines
10/10/2001EP1140173A2 Vascular endothelial cell growth factor antagonists and uses thereof
10/10/2001EP1140171A1 Methods and products for regulating lectin complement pathway associated complement activation
10/10/2001EP1140167A1 Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
10/10/2001EP1140164A2 Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
10/10/2001EP1140163A2 Combination of hepatitis b vaccine with antiviral agents
10/10/2001EP1140157A2 Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
10/10/2001EP1140154A2 Chorionic gonadotropin dna vaccines and methods
10/10/2001EP1140150A2 Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor
10/10/2001EP1140149A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
10/10/2001EP1140148A1 Shelf-stable formulation of glucagon-like peptide-1
10/10/2001EP1140147A2 hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
10/10/2001EP1140146A1 Porcine b7-1 and antibodies thereto
10/10/2001EP1140145A2 Novel exendin agonist formulations and methods of administration thereof
10/10/2001EP1140144A2 Composition of highly purified natural mixtures of type i interferon derived from leukocytes and methods
10/10/2001EP1140143A2 Ribavirin-pegylated interferon alfa induction hcv combination therapy
10/10/2001EP1140142A2 Treatment of hepatitis c virus infections with interleukin-10
10/10/2001EP1140141A2 Methods for treating cancer and for mediating chemotaxis of dendritic cells
10/10/2001EP1140140A2 Composition and method for improving function of embryonic kidney transplants
10/10/2001EP1140139A2 Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
10/10/2001EP1140138A2 Therapeutic applications of flint polypeptides
10/10/2001EP1140136A2 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
10/10/2001EP1140135A1 Cyclosporin solution
10/10/2001EP1140134A1 Agent for treating visual cell function disorder
10/10/2001EP1140133A1 Controlled release formulation comprising gnrh-ii
10/10/2001EP1140132A1 Gonadotropin releasing hormone antagonist
10/10/2001EP1140131A2 Peptides and peptide analogues designed from hfe protein and their uses in the treatment of iron overload diseases
10/10/2001EP1140130A2 Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs
10/10/2001EP1140129A1 Human mad proteins and uses thereof
10/10/2001EP1140121A1 Cryogranulation of activated protein c
10/10/2001EP1140120A2 Human brainiac-5
10/10/2001EP1140106A1 Treatment of diseases involving cyst formation
10/10/2001EP1140092A2 Method of treating sexual disturbances
10/10/2001EP1140085A1 Azabicycloalkanes as ccr5 modulators
10/10/2001EP1140077A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/10/2001EP1140052A2 Sensitizing agents for the treatment of skin lesions
10/10/2001EP1140041A2 Methods for treating conditions associated with the accumulation of excess extracellular matrix
10/10/2001EP1140027A1 Dosage forms comprising porous particles
10/10/2001EP1140025A1 Granules for oral administration, process for producing the same, and tablets produced from the granules
10/10/2001EP1140024A2 Particles for oral delivery of peptides and proteins
10/10/2001EP1140020A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles
10/10/2001EP1140019A1 Aerosol formulations for buccal and pulmonary application
10/10/2001EP1140018A1 Polyol/oil suspensions for the sustained release of proteins
10/10/2001EP1140010A2 Substrate composition and method of use for sequestration of skin irritants
10/10/2001EP1140009A2 Absorbent article composition and method of use for sequestering skin irritants
10/10/2001EP1140000A1 Osmetische oder dermatologische zusammensetzub
10/10/2001EP1139784A1 Food-induced antisecretory proteins in egg yolk
10/10/2001EP1139780A1 Method for producing granulates containing enzymes
10/10/2001EP1139755A2 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
10/10/2001EP1139753A1 Formulations for treating disease and methods of using same
10/10/2001EP1139752A1 Methods and compositions for treatment of cell proliferative disorders
10/10/2001EP1139751A1 Efficient and stable $i(in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
10/10/2001EP1139750A1 Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues
10/10/2001EP1139732A1 Msh5 ablated mice and uses therefor
10/10/2001EP1093378A4 Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
10/10/2001EP0956036A4 Anti-fibrotic agent assay
10/10/2001EP0840620B1 Il-8 antagonists for treatment of asthma
10/10/2001EP0830372B1 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
10/10/2001EP0668909B1 Transgenic, cross-linked hemoglobin
10/10/2001EP0667898B1 Uses of the tau/neurofilament protein kinase pk40
10/10/2001CN1317052A Proteases fused with variants of streptomyces subtilisin proteases inhibitor
10/10/2001CN1317047A GBS toxin receptor
10/10/2001CN1317045A Pharmaceutical uses of NAB1 and NAB2
10/10/2001CN1317043A Polypeptides and polynucleotides from coagulase-negative staphylocoui
10/10/2001CN1317015A Human anti-factor IX/IXa antibodies
10/10/2001CN1317013A Peptide fragments of cholera toxic B or enterotoxin B as vaccine adjuvants
10/10/2001CN1317011A Process for couping amino acids using bis-(trichloromethyl) carbonate
1 ... 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 ... 3163